Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Front Cell Infect Microbiol ; 10: 569709, 2020.
Article in English | MEDLINE | ID: covidwho-1004672

ABSTRACT

Accumulating evidence suggests that there are important contributions to coronavirus disease (COVID-19) from redox imbalance and improperly coordinated iron, which cause cellular oxidative damage and stress. Cells have developed elaborate redox-dependent processes to handle and store iron, and their disfunction leads to several serious diseases. Cellular reductants are important as reactive oxygen species (ROS) scavengers and to power enzymatic repair mechanisms, but they also may help generate toxic ROS. These complicated interrelationships are presented in terms of a cellular redox/iron/ROS triad, including ROS generation both at improperly coordinated iron and enzymatically, ROS interconvertibility, cellular signaling and damage, and reductant and iron chelator concentration-dependent effects. This perspective provides the rational necessary to strongly suggest that COVID-19 disrupts this interdependent triad, producing a substantial contribution to the ROS load, which causes direct ROS-induced protein and phospholipid damage, taxes cellular resources and repair mechanisms, and alters cellular signaling, especially in the more critical acute respiratory distress syndrome (ARDS) phase of the infection. Specific suggestions for therapeutic interventions using reductants and chelators that may help treat COVID-19 are discussed.


Subject(s)
COVID-19/metabolism , Iron/metabolism , Oxidative Stress , Reactive Oxygen Species/metabolism , SARS-CoV-2/metabolism , Antioxidants/metabolism , Antioxidants/therapeutic use , COVID-19/complications , Glutathione/metabolism , Hemoglobins/metabolism , Humans , Hydroxyl Radical/metabolism , Inflammation , Iron Chelating Agents/pharmacology , Iron Chelating Agents/therapeutic use , Models, Biological , Oxidation-Reduction , Reducing Agents/pharmacology , Reducing Agents/therapeutic use , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/metabolism , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL